Choksi Laboratories Ltd Downgraded to Sell Amid Mixed Technicals and Flat Financials

Quality Assessment: Weak Long-Term Fundamentals

Choksi Laboratories’ quality rating remains subdued, primarily due to its weak long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) stands at a modest 8.64%, signalling limited efficiency in generating profits from its capital base. Over the past five years, net sales have grown at an annualised rate of just 12.18%, which is relatively tepid for a healthcare services firm operating in a sector known for robust growth potential.

Moreover, the company’s ability to service debt is concerning, with an average EBIT to interest coverage ratio of only 1.68. This low ratio indicates vulnerability to interest rate fluctuations and potential liquidity constraints. The half-year financials for FY26-27 reveal further stress points: cash and cash equivalents have dwindled to a low ₹0.21 crore, and the debtors turnover ratio has dropped to 3.12 times, suggesting slower collections and potential working capital inefficiencies.

These factors collectively underpin the company’s weak quality grade, reinforcing caution among investors despite pockets of operational stability.

Valuation: From Very Attractive to Attractive

On the valuation front, Choksi Laboratories has seen a slight downgrade from a “very attractive” to an “attractive” grade. The company currently trades at a price-to-earnings (PE) ratio of 63.49, which is high relative to many peers but somewhat justified by its growth prospects. Its EV to EBITDA multiple stands at 12.11, indicating a reasonable valuation compared to the sector average, while the EV to capital employed ratio is a modest 2.69, suggesting efficient capital utilisation relative to enterprise value.

Return on Capital Employed (ROCE) and Return on Equity (ROE) are 8.95% and 7.43%, respectively, which are below industry leaders but consistent with the company’s micro-cap status. The PEG ratio of 2.38 reflects moderate growth expectations relative to earnings, signalling that while the stock is not cheap, it is not excessively overvalued either.

When benchmarked against competitors such as KMC Speciality (PE 40.41, EV/EBITDA 22.84) and Gujarat Kidney (PE 86.91, EV/EBITDA 50.06), Choksi Laboratories’ valuation appears more reasonable, albeit with a higher PE. This relative attractiveness is tempered by the company’s weaker fundamentals and recent financial performance.

Financial Trend: Flat Performance Amid Mixed Returns

The company’s recent financial trend has been largely flat, with Q1 FY26-27 results showing no significant growth. Despite this, Choksi Laboratories’ profits have risen by 26.7% over the past year, a positive sign amid a challenging operating environment. However, this profit growth contrasts with the stock’s price performance, which has declined by 23.11% over the same period, underperforming the BSE500 index’s marginal negative return of -0.31%.

Longer-term returns paint a more favourable picture, with the stock delivering a 201.74% return over three years and an impressive 844.69% over five years, vastly outperforming the Sensex’s 12.26% and 28.23% returns, respectively. This disparity suggests that while the company has demonstrated strong growth historically, recent market sentiment and operational challenges have dampened investor enthusiasm.

Institutional investors have increased their stake by 0.99% in the previous quarter, now collectively holding 7.02% of the company. This growing institutional interest may reflect confidence in the company’s long-term prospects despite short-term headwinds.

Technical Analysis: Downgrade from Bullish to Mildly Bullish

The downgrade in Choksi Laboratories’ investment rating is significantly influenced by changes in its technical profile. The technical trend has shifted from bullish to mildly bullish, reflecting a more cautious market stance. Weekly indicators such as MACD and Bollinger Bands remain bullish, supporting some upward momentum. However, monthly indicators present a more mixed picture: MACD is mildly bearish, RSI is bearish, and KST is mildly bearish, signalling potential weakening in the medium term.

Moving averages on the daily chart remain bullish, suggesting short-term strength, but the absence of a clear Dow Theory trend on the weekly chart and only a mildly bullish monthly Dow Theory signal indicate uncertainty. The lack of a definitive trend and mixed momentum indicators have contributed to the technical downgrade, tempering enthusiasm for the stock’s near-term price action.

On 10 September 2026, the stock closed at ₹173.35, up 5.00% from the previous close of ₹165.10. The 52-week high and low stand at ₹229.45 and ₹81.85, respectively, highlighting significant volatility over the past year.

Summary and Outlook

Choksi Laboratories Ltd’s downgrade from Hold to Sell reflects a comprehensive reassessment of its investment merits. While the company benefits from an attractive valuation relative to peers and has demonstrated strong long-term returns, its recent flat financial performance, weak fundamental quality metrics, and mixed technical signals have raised concerns.

Investors should weigh the company’s moderate profit growth and institutional interest against its operational challenges and subdued debt servicing capacity. The technical downgrade to mildly bullish suggests caution in the near term, despite some short-term price strength.

Given these factors, the current Sell rating advises investors to approach Choksi Laboratories with prudence, considering alternative opportunities within the healthcare services sector that may offer stronger fundamentals and clearer technical momentum.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →